Exercise of Warrants
11 September 2026
MedPal AI plc
("MedPal" or the "Company")
Warrant Exercise
MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-powered, integrated digital health and pharmacy company, announces that the Company has received a notice to exercise warrants over a total of 4,130,833 new ordinary shares of 0.0002 pence each in the Company at an exercise price of 4 pence per share ("Warrant Shares"), raising £165,233.32 for the Company.
ADMISSION AND TOTAL VOTING RIGHTS
Application will be made for the 4,130,833 Warrant Shares to be admitted to trading on AIM which is expected to occur on or around 17 September 2026 ("Admission"). The Warrant Shares will rank pari passu in all respects with the ordinary shares of the Company currently traded on AIM.
Following Admission, the Company's issued share capital will comprise 783,249,135 ordinary shares of 0.0002p each. This number will represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
For further information please contact:
Enquiries:
MedPal AI plc
Jason Drummond, Chief Executive Officer
Via Square1 Consulting
Cairn Financial Advisers LLP (Nomad)
Louise O'Driscoll / Jo Turner
+44 (0) 20 7213 0880
OAK Securities (a trading name of Merlin Partners LLP)
Tim Dainton / Calvin Man
+44 (0) 20 3973 3678
Square1 Consulting
David Bick
+44 (0) 20 7929 5599
+44 (0) 7831 381201
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDIOESFFSUFEMSEDU
